The National Health Service in England is executing a structural overhaul of its citizen facing digital channels. Driven by the strategic framework of the government’s 10-Year Health Plan (Fit for the Future) and informed by the operational diagnosis of the 2024 Darzi Review, the health service is transitioning away from a fragmented ecosystem of locally procured patient portals toward a centralised, state-curated "digital front door" anchored on the NHS App. This transition

During the initial growth cycle of consumer wearable technology, venture capital allocations and equity valuations were tethered directly to consumer electronics benchmarks: industrial design, miniaturization of components, unit shipment volume, and hardware gross margins. The contemporary investment thesis has decisively broken with this framework. Institutional capital, private equity sponsors, and Big Tech acquirers now regard consumer hardware as a low-margin, commoditise

Nelson Advisors: Specialists in European HealthTech, MedTech, Healthcare AI and Digital Health. Partnerships, Investments, Mergers & Acquisitions from $25M to $250M Enterprise Value. The European healthcare technology M&A landscape is undergoing a structural realignment, and it is happening quietly. There is no single headline moment to point to, no dramatic collapse or blockbuster deal that marks the shift. Instead, the change has been cumulative: a gradual hollowing out of

Julien Bek’s thesis, "Services: The New Software," argues that the next generation of decacorn and trillion dollar technology companies will not sell software tools to knowledge workers; instead, they will sell the completed work product directly, operating as software companies masquerading as services firms. Across the broader macroeconomic landscape, enterprises allocate approximately six dollars to human professional services for every single dollar spent on software. In

How a London communications platform and a Stockholm AI company built the NHS's fastest scaling ambient scribe, and what founders and investors should take from it. Strategic partnerships in HealthTech are announced often and delivered rarely. The press release is easy; the shared roadmap, the aligned commercial incentives and the willingness to let another company sit between you and your customer are hard. Which is why Accurx Scribe, powered by Tandem, deserves attention as

Fewer, larger, more selective: what the first half of 2026 tells us about where private capital is going in MedTech, and how investors should think about carve-outs, take-privates and the categories that are attracting the biggest cheques. The headline number for MedTech M&A in 2026 is striking. In the first half of the year, deal value was roughly 160% higher than the same period in 2025. The more interesting number sits beside it: deal count rose by just 5%. Average deal v

European HealthTech continues to see heavy capital flow toward clinical workflow automation, platform consolidation and regulatory alignment under evolving EU frameworks. Tandem Health (Sweden) raised $100M in Series B funding, backed by the EU's €5B tech startup initiative, to scale its clinical workflow and administrative AI platform across European healthcare networks. Venture capital continues shifting decisively away from standalone consumer wellness apps, heavily pr

Nine months ago, Angle Health closed what looked like a strong Series B. The San Francisco health benefits company raised $134 million in a mix of debt and equity led by Portage, bringing its total funding to just under $200 million. It was a respectable round for a company that most people outside the US employer benefits market had never heard of. Now, according to the Wall Street Journal, European mid market private equity firm Vitruvian Partners is leading a $600 Million

Every year, the NHS in England delivers roughly 120 million outpatient appointments. Two thirds of them are follow-ups. And, according to the chair of NHS England, almost nobody in the system believes this is a sensible way to spend clinical time, patient time or public money. Speaking at the King's Fund last week, one year on from the publication of the 10 Year Health Plan, Penny Dash made a remark that will resonate with anyone who has spent time in health policy circles. A

The convergence of high profile investment and digital health reflects a fundamental shift in medical care: transitioning from reactive, episodic treatment to continuous, predictive and consumer centric health management. High net worth cultural figures, particularly elite athletes such as Cristiano Ronaldo and LeBron James, alongside cultural entrepreneurs like Gwyneth Paltrow, are shifting their capital from traditional lifestyle endorsements to equity stakes in deep di

It is called Te Papa Hauora, the Christchurch Health Precinct and what began as a rebuilding project after the 2010–2011 Canterbury earthquakes has evolved into something closer to a deliberate industrial strategy. Cumulative investment across its public hospital rebuilds, university and polytechnic campuses, and commercial healthtech space now runs well past the billion dollar mark and the momentum is starting to attract attention well beyond New Zealand's shores.

Switzerland's medical technology industry is having a strange kind of year. By almost every headline measure, it is thriving: output is expanding at twice the rate of the broader Swiss economy, exports are climbing, and research spending remains among the highest of any industrial sector in the country. Yet beneath those numbers, the people who run the country's medtech companies are sounding an alarm that has been building for several years and has now become impossible to i

The NHS IT market is entering one of its most consequential growth phases in years. New analysis from Future Health Intelligence (FHI) forecasts that spending on NHS technology will climb from £6.1bn today to £8.3bn by 2030, adding more than £2bn in new market value over the next four years and cementing digital health as one of the fastest-growing corners of the UK public sector IT landscape. For an industry that has weathered its share of false starts and stop-go funding cy

Transformation Capital, the largest dedicated digital health venture and growth equity firm, has announced the final close of its fourth fund, Transformation Capital Fund IV, at an $850 million hard cap. The raise came in oversubscribed, with the firm completing the close this summer after exceeding its original target. It's a milestone that says as much about the state of digital health investing in 2026 as it does about Transformation Capital itself, and it's worth unpackin

There was no keynote, no press release, no carefully art-directed product shot. Apple's latest acquisition surfaced the way most of its acquisitions do: through a regulatory filing nobody was supposed to notice. Buried in the European Union's database of mergers likely to be significant in the region, a single entry revealed that Apple had acquired Sonera, a Berkeley born startup that builds non-invasive sensors capable of reading neural signals straight from the brain and bo